Diagnostics and Screening
An Introduction to Diagnostics and Screening
Early detection of tumours is essential to increase the likelihood of complete remission. Screening strategies are not without risk; for example, mammography and prostate-specific antigen screening can lead to the detection of indolent lesions and subsequent overtreatment. Precision medicine has improved screening and diagnostic approaches; tumour-typing of breast tumours for oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 has informed treatment options. Many non-invasive diagnostic tools can be used directly at the point of care. It is hoped that advances in the genomic classification may lead to the identification of high-risk individuals in other types of cancer.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Diagnostics and Screening Content
Molecular Diagnostics in the Screening, Detection and Diagnosis of Cancer
European Oncology & Haematology. 2019;15(2):84–5
Molecular diagnosis and screening of cancer can be approached either in a broad, high-volume manner, or through using targeted, informed searches for specific genes. Technique selection will be critical in balancing patient benefit against healthcare resource cost, and physicians will need to consider how to prioritise their investigations in order to support accurate and efficacious […]
Judy Garber, ASCO 2019 – Progress and challenges in clinical cancer genetics
Following her Award Lecture, ‘Progress and Challenges in Clinical Cancer Genetics’, Judy Garber further discusses this topic at the ASCO 2019 annual meeting. The progress made in genetic testing and the benefits/challenges that remain are covered. Questions 1. What progress has been made in genetic testing for cancer susceptibility among individuals at high genetic risk, […]
Large-scale Genomic Testing Facilitates Precision Medicine in Routine Cancer Care
Oncology & Hematology Review. 2019;15(1):25–6 DOI: https://doi.org/10.17925/OHR.2019.15.1.25
Over the last decade, genomics has become an increasingly important part of cancer care. In some tumor types, such as lung cancer and melanoma, genetic profiling for actionable mutations has become standard clinical practice.1,2 The development of novel targeted molecular therapies together with the increased availability of next-generation genomic sequencing has led to an interest […]
Wadie Bahou, ASH 2018 – Platelets and Platelet-related Biomarkers in Tumor Biology and Metastasis
Dr Wadie Bahou answers our questions about the role of platelets in tumor biology and metastasis and the significance and usefulness of platelet-related biomarkers in the detection and monitoring of hematologic and oncologic diseases. Questions: 1. What is the role of platelets in tumor biology and metastasis? (0:10) 2. Which platelet-related biomarkers have proven useful […]
Detecting an ALK Rearrangement via Liquid Biopsy Enabled a Targeted Therapy-based Approach for Treating a Patient with Advanced Non-small Cell Lung Cancer
Oncology & Hematology Review. 2018;14(1):38–41 DOI: https://doi.org/10.17925/OHR.2018.14.1.38
It has been clearly established that non-small cell lung cancers (NSCLCs) associated with known molecular drivers (e.g., rearrangement of the ALK gene, or mutations activating the epidermal growth factor receptor [EGFR] gene) respond favorably to targeted, first-line therapies compared with standard chemotherapy.1,2 The National Comprehensive Cancer Network recommends EGFR and ALK testing (category 1), as […]
Radiopharmaceuticals for the Detection of Recurrent Prostate Cancer
European Oncology & Haematology. 2018;14(1):16–17 DOI: https://doi.org/10.17925/EOH.2018.14.1.16
Q. What are the limitations of current methods of detecting biochemical recurrence of prostate cancer? The recommended imaging techniques for the diagnosis of metastases in prostate cancer are 99m-Tc bone scintigraphy for bone metastases and computed tomography (CT) or magnetic resonance imaging (MRI) for lymph nodes. These two techniques have a very low sensitivity–specificity for detecting […]
ESMO 2017 Panel Discussion, Part 5 – Staging and New Staging Guideline
Mario Mandala, Vanna Cahiarrion-Sileni and Jean-Jacques Grob discuss the issues with staging and the new staging guidelines at ESMO 2017. Support: The filming of this video was supported by Novartis.
ESMO 2017 – Marwan Fakih Interview
Marwan Fakih discusses the implications of primary tumour location on biological therapy in metastatic colorectal cancer.
Molecular Diagnostics in Breast Cancer Routine Practice
European Oncology & Haematology, 2017;13(1):74–9 DOI: https://doi.org/10.17925/EOH.2017.13.01.74
Adjuvant systemic treatment of breast cancer is moving away from the limited portfolio of traditional hormonal drugs and chemotherapy, towards a gamma of novel anti-hormonal and chemotherapeutic drugs, immunotherapeutic approaches and small molecules. All these therapeutic approaches are unfortunately effective in a limited number of patients and are often associated with high costs and significant […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!